



Announcement Summary

Entity name

INHALERX LIMITED

Announcement Type

New announcement

Date of this announcement

18/10/2024

The Proposed issue is:

A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
New class-code to be confirmed	Oct24 Funding Facility Options Exp 2029 min Ex of \$0.025	38,449,145

Proposed +issue date

28/2/2025

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

INHALERX LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ACN

Registration Number

611845820

1.3 ASX issuer code

IRX

1.4 The announcement is

New announcement

1.5 Date of this announcement

18/10/2024

1.6 The Proposed issue is:

A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

Yes

7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	28/11/2024	Estimated	No

Comments

A General Meeting of the Company will be held to seek approval to issue these securities.

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

New class

Will the proposed issue of this +security include an offer of attaching +securities?

No

Details of +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?

Yes

Will the entity be seeking quotation of the 'new' class of +securities on ASX?

No

ASX +security code

New class-code to be confirmed

+Security description

Oct24 Funding Facility Options Exp 2029 min Ex of \$0.025

+Security type

Options

Number of +securities proposed to be issued

38,449,145

**Offer price details****Are the +securities proposed to be issued being issued for a cash consideration?**

No

Please describe the consideration being provided for the +securities

The Options are to be issued to secure the funds under the Facility Agreement announced 18 October 2024 by incentivising the Lender to assist the Company in completing the clinical trials for IRX-211 and IRX-616a.

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

0.025000

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Options details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 0.0250	31/12/2029

Details of the type of +security that will be issued if the option is exercised

IRX : ORDINARY FULLY PAID

Number of securities that will be issued if the option is exercised

38,449,145 IRX ordinary fully paid shares

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

Please refer the announcement titled "\$38.5m Funding to Fully Fund Clinical Development Plans" lodged with ASX on 18 October 2024:

<https://www.asx.com.au/markets/company/irx>

Part 7C - Timetable

7C.1 Proposed +issue date

28/2/2025

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?
Yes**7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1**

28/11/2024



7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

No

7E.2 Is the proposed issue to be underwritten?

No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

N/A

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

The Options are to be issued to secure the funds under the Facility Agreement announced 18 October 2024 by incentivising the Lender to assist the Company in completing the clinical trials for IRX-211 and IRX-616a.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

No

7F.2 Any other information the entity wishes to provide about the proposed issue

Please refer the announcement titled "\$38.5m Funding to Fully Fund Clinical Development Plans" lodged with ASX on 18 October 2024:

<https://www.asx.com.au/markets/company/irx>